Phase 2 trials are designed to evaluate what?

Phase 2 trials are designed to evaluate what?

• A. Phase 1 clinical trials
• B. Post-Marketing Surveillance
• C. Phase 3 clinical trials
• D. Phase 2 clinical trials

Answer: (D)

Phase 2 trials focus on whether the drug actually works in the target patient population and how safe it is at doses that will be used clinically. After Phase 1 establishes basic safety and pharmacokinetics, Phase 2 tests for meaningful therapeutic effect in patients with the disease, helps establish the optimal dose (dose–response), and further characterizes common adverse effects. This stage bridges initial safety with large-scale confirmation, which occurs in Phase 3. Post-marketing surveillance happens after approval, monitoring long-term safety in the general population. So Phase 2 trials are designed to evaluate efficacy signals and dosing, along with safety, in patients with the condition.

Phase 2 trials focus on whether the drug actually works in the target patient population and how safe it is at doses that will be used clinically. After Phase 1 establishes basic safety and pharmacokinetics, Phase 2 tests for meaningful therapeutic effect in patients with the disease, helps establish the optimal dose (dose–response), and further characterizes common adverse effects. This stage bridges initial safety with large-scale confirmation, which occurs in Phase 3. Post-marketing surveillance happens after approval, monitoring long-term safety in the general population. So Phase 2 trials are designed to evaluate efficacy signals and dosing, along with safety, in patients with the condition.